Literature DB >> 17051491

Proton pump inhibitors and hospitalization for Clostridium difficile-associated disease: a population-based study.

Donna O Lowe1, Muhammad M Mamdani, Alexander Kopp, Donald E Low, David N Juurlink.   

Abstract

BACKGROUND: Previous studies have examined the association between proton pump inhibitor (PPI) use and the risk of Clostridium difficile-associated disease (CDAD), with conflicting results. Whether outpatient PPI use influences the risk of hospital admission for CDAD among older patients who have recently been treated with antibiotics is unknown.
METHODS: We conducted a population-based, nested case-control study of linked health care databases in Ontario, Canada, from 1 April 2002 through 31 March 2005. We identified patients aged > or = 66 years who were hospitalized for CDAD within 60 days of receiving outpatient antibiotic therapy. Each case patient with CDAD was matched with 10 control subjects on the basis of age, sex, and details of antibiotic use (antibiotic class, timing, and number of antibiotics used). PPI use by case patients and control subjects was categorized as current (within 90 days), recent (91-180 days), or remote (181-365 days). We used conditional logistic regression to estimate the odds ratio for the association between outpatient PPI use and risk of hospitalization for CDAD.
RESULTS: We identified 1389 case patients and 12,303 matched control subjects. Case patients were no more likely than control subjects to have received a PPI in the preceding 90 days (adjusted odds ratio, 0.9; 95% confidence interval, 0.8-1.1). Similarly, we found no association between hospitalization for CDAD and more remote use of PPIs.
CONCLUSIONS: Among community-dwelling older patients, PPI use is not a risk factor for hospitalization with CDAD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17051491     DOI: 10.1086/508453

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  41 in total

Review 1.  Review of medical and surgical management of Clostridium difficile infection.

Authors:  B Faris; A Blackmore; N Haboubi
Journal:  Tech Coloproctol       Date:  2010-05-08       Impact factor: 3.781

2.  Hospital-acquired Clostridium difficile infection: determinants for severe disease.

Authors:  J M Wenisch; D Schmid; H-W Kuo; E Simons; F Allerberger; V Michl; P Tesik; G Tucek; C Wenisch
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-12-31       Impact factor: 3.267

Review 3.  Proton pump inhibitors: an update of their clinical use and pharmacokinetics.

Authors:  Shaojun Shi; Ulrich Klotz
Journal:  Eur J Clin Pharmacol       Date:  2008-08-05       Impact factor: 2.953

4.  Clostridium difficile infection in the community: are proton pump inhibitors to blame?

Authors:  Daniel E Freedberg; Julian A Abrams
Journal:  World J Gastroenterol       Date:  2013-10-28       Impact factor: 5.742

5.  Does PPI therapy predispose to Clostridium difficile infection?

Authors:  Chaitanya Pant; Phillip Madonia; Anil Minocha
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-09       Impact factor: 46.802

6.  Interventions to curb the overuse of Acid-suppressive medications on an inpatient general medicine service.

Authors:  Randolph E Regal; Amanda D Osta; Vikas I Parekh
Journal:  P T       Date:  2010-02

Review 7.  Clostridium difficile infection: new insights into management.

Authors:  Sahil Khanna; Darrell S Pardi
Journal:  Mayo Clin Proc       Date:  2012-11       Impact factor: 7.616

8.  Clostridium difficile: the emerging epidemic.

Authors:  Nasia Safdar
Journal:  Mayo Clin Proc       Date:  2012-11       Impact factor: 7.616

9.  Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection.

Authors:  Kevin A Brown; Nagham Khanafer; Nick Daneman; David N Fisman
Journal:  Antimicrob Agents Chemother       Date:  2013-03-11       Impact factor: 5.191

10.  [Long-term use of proton pump inhibitors: who needs prophylaxis?].

Authors:  M Scheurlen
Journal:  Internist (Berl)       Date:  2013-03       Impact factor: 0.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.